Evidence map›Paper›PMID 25679516›Full record

ArticlePLoS pathogens2015

Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii.

Edward Geisinger, Ralph R Isberg

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 205 papers.

0numbers the graph read from it
0cells of the map it votes in
205citing papers in PubMed
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

205 citing papers in PubMed, 543 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Changes in Susceptibility Profiles ofJournal of clinical medicine · 2026
    Article
  10. Membrane-Focused Strategies AgainstAntibiotics (Basel, Switzerland) · 2026
    Review
  11. Article
  12. Article
  13. Control of cell division by anbioRxiv : the preprint server for biology · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Resistance, heteroresistance, and fitness costs drive colistin treatment failure duringProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  20. Isolation and whole-genome characterization of multidrug-resistant Acinetobacter baumannii from Indian retail meat: unveiling high-risk clones and zoonotic transmission threats via comparative genomics.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article

145 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Edward GeisingerDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, United States of America.
Ralph R IsbergDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, United States of America; Howard Hughes Medical Institute, Boston, Massachusetts, United States of America.
Howard Hughes Medical Institute · USTufts University · US

Funding

Type VI Protein Secretion in an Emerging Multidrug-Resistant PathogenF32AI098358 · NIAID · TUFTS UNIVERSITY BOSTON · PI GEISINGER, EDWARD · 2012 to 2014
$168k
Howard Hughes Medical InstituteNIAID NIH HHS F32 AI098358NIAID NIH HHS F32AI098358
6 · The paper itself

Abstract

Acinetobacter baumannii is an opportunistic pathogen of increasing importance due to its propensity for intractable multidrug-resistant infections in hospitals. All clinical isolates examined contain a conserved gene cluster, the K locus, which determines the production of complex polysaccharides, including an exopolysaccharide capsule known to protect against killing by host serum and to increase virulence in animal models of infection. Whether the polysaccharides determined by the K locus contribute to intrinsic defenses against antibiotics is unknown. We demonstrate here that mutants deficient in the exopolysaccharide capsule have lowered intrinsic resistance to peptide antibiotics, while a mutation affecting sugar precursors involved in both capsule and lipopolysaccharide synthesis sensitizes the bacterium to multiple antibiotic classes. We observed that, when grown in the presence of certain antibiotics below their MIC, including the translation inhibitors chloramphenicol and erythromycin, A. baumannii increases production of the K locus exopolysaccharide. Hyperproduction of capsular exopolysaccharide is reversible and non-mutational, and occurs concomitantly with increased resistance to the inducing antibiotic that is independent of the presence of the K locus. Strikingly, antibiotic-enhanced capsular exopolysaccharide production confers increased resistance to killing by host complement and increases virulence in a mouse model of systemic infection. Finally, we show that augmented capsule production upon antibiotic exposure is facilitated by transcriptional increases in K locus gene expression that are dependent on a two-component regulatory system, bfmRS. These studies reveal that the synthesis of capsule, a major pathogenicity determinant, is regulated in response to antibiotic stress. Our data are consistent with a model in which gene expression changes triggered by ineffectual antibiotic treatment cause A. baumannii to transition between states of low and high virulence potential, which may contribute to the opportunistic nature of the pathogen.

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsBacterial CapsulesDisease Models, AnimalDrug Resistance, Multiple, BacterialFemaleMiceMice, Inbred C57BLPolysaccharides, BacterialAnti-Bacterial AgentsPolysaccharides, Bacterial

Identifiers

PMID25679516
PMCPMC4334535
OpenAlexW1992500937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.